Dialysis News and Research

Latest Dialysis News and Research

Illinois profs receive grant to work with kidney dialysis patients

University of Illinois scientists will learn whether protein supplements and cycling during treatments can help dialysis patients fight cardiovascular disease and retain physical function, thanks to a $2.1 million grant from the National Institutes of Health (NIH).

2 Sep 2010

Calif. allows safety-net coverage cost increase; Georgia illegal immigrant dialysis agreement reached

"As state leaders blast giant health insurers for raising rates, Gov. Arnold Schwarzenegger's administration has quietly allowed hefty increases for thousands of sick or jobless Californians who must rely on expensive safety-net coverage -- if they want insurance at all.

2 Sep 2010

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

Kidney failure may accompany or complicate transplantation of the liver, heart, or lung. Because increasing numbers of individuals are receiving non-kidney transplants, researchers have wondered whether more of such patients are being listed for kidney transplants.

2 Sep 2010

AngioDynamics launches new access kit for VenaCure EVLT system to treat varicose veins

AngioDynamics announced today the launch of a new access kit allowing fewer procedure steps and faster procedure time for physicians using the VenaCure EVLT system's NeverTouch® gold-tip laser fiber to treat varicose veins.

30 Aug 2010

Hemoglobin variability does not increase mortality in European hemodialysis patients: Study

Fluctuations in blood composition that often arise from commonly used therapies among kidney disease patients are not an independent predictor of adverse outcomes for European hemodialysis patients, according to a study appearing in an upcoming issue of the Journal of the American Society Nephrology. The results suggest that although hemoglobin variability is common in kidney disease patients, it does not appear to increase their likelihood of dying early.

27 Aug 2010

Aethlon Medical receives approval for Chronic HCV Infection treatment

Aethlon Medical, Inc., the pioneer in developing therapeutic filtration devices to address infectious disease and cancer, announced today that the Medanta Independent Ethics Committee (MIEC) at Medanta, The Medicity Institute (Medicity) has approved a treatment program entitled "Use of the Aethlon Hemopurifier in Treating Chronic HCV Infection in Combination with Standard of Care (SOC) Drug Therapy."

26 Aug 2010

Veteran Affairs to use Redsense alarm to detect blood leakage during hemodialysis

The Redsense alarm will be required for use in Veteran Affairs' dialysis centers. The safety alert, based on research from Veteran Affairs National Center for Patient Safety, marks an important step for the only alarm that detects blood leakage during hemodialysis.

26 Aug 2010

Fresenius Medical Care inks agreement to acquire Gambro's worldwide peritoneal dialysis business

Fresenius Medical Care AG & Co. KGaA, the world's largest provider of dialysis products and services, today announced that it has signed an agreement to acquire Gambro's worldwide peritoneal dialysis (PD) business. Gambro has decided to prioritize its investments in the hemodialysis field. Fresenius Medical Care is taking advantage of this opportunity to expand its activities in the homecare market, especially in Europe and Asia-Pacific.

26 Aug 2010

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

Celgene Corporation today announced that information was posted on the FDA Web site indicating that an Abbreviated New Drug Application (ANDA) has been received by the Office of Generic Drugs (OGD) containing a "Paragraph IV" patent certification, for REVLIMID (lenalidomide) 25 mg capsules. Celgene has not yet received the Paragraph IV notification letter identifying the filer.

25 Aug 2010

BioTrends' online survey provides in-depth view of dialysis vascular access market

BioTrends Research Group, Inc. recently published its TreatmentTrends: Vascular Access report. This report is based on online survey results from over 150 physicians (general nephrologists, surgeons, interventional radiologists and interventional nephrologists).

25 Aug 2010

'Pre-vascularization' of device prior to implantation sustains circulation and suppresses scar formation

By creating a unique system of blood vessels that is engineered to interact with the tissue surrounding an implanted device, the longevity and function of these devices may be better preserved, according to a study led by researchers in the University of Louisville/ Jewish Hospital's Cardiovascular Innovation Institute (CII).

24 Aug 2010

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Celgene International Sàrl announced that REVLIMID (lenalidomide) has been granted full marketing authorization by Japan's Ministry of Health, Labour and Welfare (MHLW) for the treatment of patients with myelodysplastic syndromes (MDS) associated with a deletion 5q cytogenic abnormality. REVLIMID was also approved in June 2010 in combination with dexamethasone, for the treatment of patients with relapsed or refractory multiple myeloma who have received at least one prior standard therapy.

20 Aug 2010

Donor kidneys from deceased as good as those from brain-dead: Study

According to a new study from the UK, transplanted kidneys from patients whose hearts have stopped perform just as well as those from patients who are brain-dead but still alive. The former have been earlier considered to be weaker since the heart had stopped pumping blood into them before transplant. The study was published online by the The Lancet.

20 Aug 2010

70% rise in kidney disease in Australia over past 7 years: Report

According to a report released today by the Australian Institute of Health and Welfare (AIHW), with the rise of type II diabetes patients, there is increasing number of hospitalizations related to chronic kidney disease in Australia.

18 Aug 2010

FDA grants orphan drug designation to NephRx's lead product NX001

NephRx Corporation today announced that the U.S. Food and Drug Administration has granted orphan drug designation to its lead product NX001 for the prevention of delayed graft function in renal transplant recipients. NX001 is a kidney growth factor peptide that has demonstrated good safety and promising efficacy in two animal models of acute renal failure.

18 Aug 2010

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Hospitals vary in how they detect and treat drug-resistant staph infections, but most follow national guideline recommendations, according to researchers at the University of Illinois at Chicago.

18 Aug 2010

Trauma center care cost-effective for all patients: Report

Trauma center care not only saves lives, it is a cost-effective way of treating major trauma, according to a new report from the Johns Hopkins Bloomberg School of Public Health's Center for Injury Research and Policy. Although treatment at a trauma center is more expensive, the benefits of this approach in terms of lives saved and quality of life-years gained outweigh the costs. The study finds that the added cost of treatment at a trauma center versus nontrauma center is only $36,319 for every life-year gained or $790,931 per life saved.

18 Aug 2010

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Before today, millions of Canadians living with chronic kidney disease did not have a strong online advocacy presence. Improving Patient Advocacy in Chronic Kidney Disease and The Kidney Foundation of Canada are now joining forces to provide an effective resource. Together, they are launching www.impackd.ca, a microsite of www.kidney.ca that is specifically designed for Canadians affected by chronic kidney disease.

17 Aug 2010

Mesa Labs first-quarter fiscal 2011 GAAP net income increases 29% to $1.32 million

Mesa Laboratories, Inc. today reported a fifty percent increase in revenue for the fiscal first quarter ended June 30, 2010.

16 Aug 2010

American CareSource second-quarter revenues decrease to $16.0 million

American CareSource Holdings Inc. today announced second quarter 2010 revenues of $16.0 million compared to $17.1 million in the corresponding prior year quarter. Net income for the second quarter 2010 was $299,000, or $0.02 per diluted share, compared to $534,000, or $0.01 per diluted share, in the corresponding prior year quarter. Net income for the second quarter 2010 included a federal income tax provision of $137,000, or $0.01 per diluted share, which was not included in net income for the second quarter 2009.

13 Aug 2010

Dialysis News and Research

Latest Dialysis News and Research

Illinois profs receive grant to work with kidney dialysis patients

Calif. allows safety-net coverage cost increase; Georgia illegal immigrant dialysis agreement reached

Non-kidney transplant patients likely to undergo kidney transplant prior to dialysis: Study

AngioDynamics launches new access kit for VenaCure EVLT system to treat varicose veins

Hemoglobin variability does not increase mortality in European hemodialysis patients: Study

Aethlon Medical receives approval for Chronic HCV Infection treatment

Veteran Affairs to use Redsense alarm to detect blood leakage during hemodialysis

Fresenius Medical Care inks agreement to acquire Gambro's worldwide peritoneal dialysis business

Celgene to enforce REVLIMID intellectual property rights following receipt of Paragraph IV notification letter

BioTrends' online survey provides in-depth view of dialysis vascular access market

'Pre-vascularization' of device prior to implantation sustains circulation and suppresses scar formation

Celgene receives Japan's MHLW approval for REVLIMID in deletion 5q myelodysplastic syndrome patients

Donor kidneys from deceased as good as those from brain-dead: Study

70% rise in kidney disease in Australia over past 7 years: Report

FDA grants orphan drug designation to NephRx's lead product NX001

Policies, practices concerning MRSA differ among acute-care hospitals in the U.S.: Researchers

Trauma center care cost-effective for all patients: Report

ImPACKD, The Kidney Foundation of Canada launch online resource for CKD patients

Mesa Labs first-quarter fiscal 2011 GAAP net income increases 29% to $1.32 million

American CareSource second-quarter revenues decrease to $16.0 million

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Dialysis News and Research

Latest Dialysis News and Research

From street to lab: Advancing controlled substance testing with handheld Raman and FTIR

Reimagining light scattering for biotherapeutics

Empowering genomics research with cloud-based innovation

Newsletters you may be interested in